pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
raps·Sep 15·1 min read
save

Experts review five decades of regulatory evolution at RAPS Convergence 2026

Sep 15, 2026·read at raps ↗RegulatoryNeutral

At the opening plenary of RAPS Convergence 2026 in Charlotte, NC, specialists in medical device and pharmaceutical regulatory affairs gathered to discuss the field’s trajectory.

They reflected on how regulatory practice has transformed over the past fifty years, highlighting milestones such as greater global harmonization, the rise of digital tools, and changing agency expectations.

The speakers stressed that future professionals must remain adaptable, leverage new technologies, and work collaboratively across sectors to address the ongoing regulatory challenges.

source

This writeup was produced by pharmadog from original reporting by raps.

Original headline: “Convergence: Experts discuss the past, present, and future of regulatory”

read at raps ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1d agoHHS will permit compounding of six peptides ahead of formal rulemakingraps
  • 1d agoFDA revises guidance on essential drug delivery device performanceraps
  • 1d agoRecon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetesraps
  • 1d agoEuro Roundup: EMA and African counterpart create guidance on Ebola vaccine clinical trialsraps
  • 2d agoFDA drafts guidance on submitting IDEs via eSTAR ahead of transitionraps